Last $13.29 USD
Change Today -0.08 / -0.60%
Volume 706.0K
As of 8:10 PM 08/22/14 All times are local (Market data is delayed by at least 15 minutes).

endologix inc (ELGX) Snapshot

Open
$13.37
Previous Close
$13.37
Day High
$13.57
Day Low
$13.15
52 Week High
12/2/13 - $18.85
52 Week Low
04/15/14 - $11.47
Market Cap
889.8M
Average Volume 10 Days
549.0K
EPS TTM
$-0.29
Shares Outstanding
67.0M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ENDOLOGIX INC (ELGX)

Related News

No related news articles were found.

endologix inc (ELGX) Related Businessweek News

No Related Businessweek News Found

endologix inc (ELGX) Details

Endologix, Inc. develops, manufactures, markets, and sells medical devices for the treatment of abdominal aortic aneurysms in the United States, Europe, and rest of the world. It provides minimally-invasive endovascular repair (EVAR) products that consist of stent graft and catheter delivery system under the Powerlink, IntuiTrak, AFX, and VELA brand names. The company also offers endovascular sealing product that is based on the Nellix platform to seal the aneurysm, as well as provides blood flow to the legs through two blood lumens. In addition, it offers aortic extensions and limb extensions, which attach to the main body of its EVAR device, enabling physicians to customize it to fit the patient’s anatomy; and accessories, including guidewires, snares, and catheter introducer sheaths that facilitate the optimal delivery of its EVAR products. Endologix, Inc. sells its products through direct sales force, a network of agents, and independent distributors. The company was formerly known as Radiance Medical Systems, Inc. and changed its name to Endologix, Inc. in May 2002. Endologix, Inc. was founded in 1992 and is headquartered in Irvine, California.

endologix inc (ELGX) Top Compensated Officers

Chairman of the Board and Chief Executive Off...
Total Annual Compensation: $897.5K
President
Total Annual Compensation: $531.7K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $406.2K
Vice President of Operations
Total Annual Compensation: $355.8K
Vice President of Human Resources
Total Annual Compensation: $169.5K
Compensation as of Fiscal Year 2013.

endologix inc (ELGX) Key Developments

Endologix Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2014; Revised Earnings Guidance for 2014

Endologix Inc. reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2014. For the quarter, the company reported global revenue of $38.3 million, a 13% increase from $34.0 million in the second quarter of 2013. The company reported a net loss of $9.0 million, or $0.14 per diluted share, compared with net income of $5.7 million, or $0.09 per diluted share for the second quarter of 2013. The company reported adjusted net loss of $3.8 million or $0.06 per share, compared with an adjusted net loss for the second quarter of 2013 of $1.9 million, or $0.03 per share. Loss from operations was $3.77 million compared to $2.52 million reported a year ago. Net loss before income tax benefit was $9.07 million compared to net income before income tax expenses of $5.53 million reported a year ago. Adjusted LBITDA was $0.95 million or $0.02 per share compared to adjusted EBITDA of $0.46 million or $0.01 per share reported a year ago. For the six months, global revenue increased 12% to $71.6 million compared to $63.7 million for the six months ended June 30, 2013. The company reported a net loss of $3.7 million, or $0.06 per diluted share, compared to a net loss of $3.7 million, or $0.06 per diluted share, for the six months ended June 30, 2013. The company reported an adjusted net loss of $8.9 million or $0.14 per share, compared with an adjusted net loss for the six months ended June 30, 2013 $6.1 million, or $0.10 per share. Loss from operations was $9.1 million compared to $7.01 million reported a year ago. Net loss before income tax benefit was $3.56 million compared to $3.47 million reported a year ago. Adjusted LBITDA was $4.0 million or $0.06 per share compared to $0.064 million reported a year ago. The company is narrowing its full year 2014 financial guidance, within the previous guidance range. The company anticipates 2014 revenue to be in the range of $148 million to $152 million, representing growth of 12% to 15% from 2013, compared to the previous range of $146 million to $152 million. The company anticipates an adjusted net loss per share in 2014 of $0.27 to $0.33 and an adjusted EBITDA per share of $0.10 to $0.16 compared to the previous adjusted EBITDA per share range of $0.04 to $0.17. The company has adjusted its geographic mix expectations with the U.S. revenue growth now expected to be 4% to 6% against 6% to 10% previously, and international revenue growth now expected to be 42% to 46% compared to 26% to 30% previously. The company continues to expect full year 2014 gross margin to be in a range of 73% to 75%. The company’s projected 2014 GAAP guidance is $0.24 to $0.30 loss per share. The company expects in 2014 with approximately $101 million to $106 million in cash using between $20 million to $25 million in 2014. 2014 cash use includes approximately $12 million in capital expenditures, primarily for leasehold improvements and equipment for its new facility in Irvine to support its current and expected revenue growth, and increase in working capital for accounts receivable and inventories consistent with its growth. With the remaining cash of over $100 million at year end, the company believes it has sufficient cash resources to continue to fund the business in future years.

Endologix Inc. to Report Q2, 2014 Results on Jul 30, 2014

Endologix Inc. announced that they will report Q2, 2014 results at 5:00 PM, Eastern Standard Time on Jul 30, 2014

Endologix Inc., Q2 2014 Earnings Call, Jul 30, 2014

Endologix Inc., Q2 2014 Earnings Call, Jul 30, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ELGX:US $13.29 USD -0.08

ELGX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ELGX.
View Industry Companies
 

Industry Analysis

ELGX

Industry Average

Valuation ELGX Industry Range
No financial data is available for ELGX.
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ENDOLOGIX INC, please visit www.endologix.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.